A lawsuit belonging to the class of federal securities has been filed against the therapeutics company, Voyager Therapeutics, Inc. It is done so for the Eastern District of the city of New York in the State District Court of the United States of America.
The lawsuit that has been filed, is done on a group of investors’ behalf. The group consists of all those people who invested, purchased, or acquired the securities of the Voyager. That is between the 1st of the month of June in the year 2017 till the 9th of November 2020.
Voyager And Its VY-HTT01 Issue
According to sources, anybody will be able to request an appeal from the court, a proposed-class lead plaintiff they have faced losses while making an investment in the shares of the company. However, this has to be done before the 24th of March in the year 2021.
Voyager is a company of the gene therapy from the clinical stage. The company puts its focus on the development of various treatments. These treatments, however, are only carried out for those suffering from severe kinds of diseases related to neurology. What is also included in the preclinical program of the company, is VY-HTT01 for the inherited condition disease, popularly known as Huntington’s disease.
Voyager issued a release of press on 12th October 2020 with regard to its submission of VY-HTT01for the Huntington’s disease treatment, to the FDA of the US. They claimed that it was placed on some kind of clinical hold which had a pending effect on the matters of manufacturing. Following the situation, there was another press release by the company. It was done so on the 9th of November. As a result of the November press release, the stock price of Voyager went down from 2.60 USD per share to somewhere near 8.60 USD.